A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects - PubMed (original) (raw)

Clinical Trial

. 2011 Feb 24;29(10):1948-58.

doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

Sharon E Frey, Marnie Elizaga, Barbara Metch, Stephen C De Rosa, Paulo F Barroso, Georgia Tomaras, Massimo Cardinali, Paul Goepfert, Artur Kalichman, Valérie Philippon, M Juliana McElrath, Xia Jin, Guido Ferrari, Olivier D Defawe, Gail P Mazzara, David Montefiori, Michael Pensiero, Dennis L Panicali, Lawrence Corey; NIAID HIV Vaccine Trials Network

Affiliations

Clinical Trial

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects

Michael C Keefer et al. Vaccine. 2011.

Abstract

We evaluated replication-defective poxvirus vectors (modified vaccinia Ankara [MVA] and fowlpox [FPV]) in a homologous and heterologous vector prime-boost vaccination regimen containing matching HIV inserts (MVA-HIV and FPV-HIV) given at months 0, 1, 3, 5 and 7 in 150 healthy HIV-negative vaccinia-naïve participants. FPV-HIV alone was poorly immunogenic, while the high dose (10(9)pfu/2 ml) of MVA-HIV alone elicited maximal responses after two injections: CD4+ and CD8+ T-cell responses in 26/55 (47.3%) and 5/60 (8.3%) of participants, respectively, and IFN-γ ELISpot responses in 28/62 (45.2%). The infrequent CD8+ T-cell responses following MVA-HIV priming were boosted only by the heterologous (FPV-HIV) construct in 14/27 (51.9%) of participants post 4th vaccination. Alternatively, HIV envelope-specific binding antibodies were demonstrated in approximately two-thirds of recipients of the homologous boosting regimen, but in less than 20% of subjects after the heterologous vector boost. Thus, a heterologous poxvirus vector prime-boost regimen can induce HIV-specific CD8+ T-cell and CD4+ T-cell responses, which may be an important feature of an optimal regimen for preventive HIV vaccination.

Trial registration: ClinicalTrials.gov NCT00083603.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest statement: none reported

Figures

Figure 1

Figure 1. Maximum severity of local pain or tenderness (panel A) and of systemic symptoms (panel B) following each of the 5 study injections

Onset of a reaction was within the first 3 days following a study injection. Reactions were followed to resolution to determine the maximum severity. Systemic reactions included malaise/fatigue, headache, chills, myalgia, arthralgia, nausea and vomiting. Groups include both vaccinees and controls who received empty pox vectors. Data are included from all participants in Part B of the study, plus those from Part A who received the same regimen and dosage as the Part B groups.

Figure 2

Figure 2. Ex-vivo HIV-specific CD4+ and CD8+ T-cells induced by heterologous vector (M/F) and homologous vector (M/M) regimens

The percentage of CD4+ (panels A, C and E) and CD8+ (panels B, D and F) T-cells producing γ-interferon (IFN- γ) and/or interleukin-2 (IL-2) in response to Env, Gag, Pol and/or Nef peptide pools (panels A and B), Env peptide pools alone (panels C and D) or Gag peptide pools alone (panels E and F) 2 weeks after the indicated immunization and at the final study visit as measured by intracellular staining assay. Responders are shown in colored circles (red = M/F; blue = M/M; groups include all participants in Part B of the study, plus those from Part A who received the same regimen and dosage as the Part B groups) and non-responders in gray triangles. The boxplots show the distribution of responses in positive responders only. The box indicates the median and interquartile range (IQR); whiskers extend to the furthest point within 1.5 times the IQR from the upper or lower quartile. Numbers at the top of each panel show the number of responders / number with assay result and the percent with positive response. Pol and Nef are not shown due to infrequent responses.

Figure 3

Figure 3. HIV protein-specific CD4+ and CD8+ T-cell responses induced by heterologous vector (M/F) and homologous vector (M/M) regimens

Number of study participants with HIV gene-specific responses among CD4+ T-cells at 2 weeks post 2nd vaccination (panel A); CD8+ T-cells at 2 weeks post 2nd vaccination (panel B), CD4+ T-cells at 2 weeks post 4th vaccination (panel C), and CD8+ T-cells at 2 weeks post 4th vaccination (panel D).as measured by intracellular staining assay. Groups include all participants in Part B of the study, plus those from Part A who received the same regimen and dosage as the Part B groups. No participants had positive responses to >2 proteins at these timepoints.

Figure 4

Figure 4. HIV-specific CD4+ and CD8+ T-cells producing multiple cytokines induced by heterologous vector (M/F) and homologous vector (M/M) regimens at 2 weeks post 4th vaccination

For each panel, the left graph shows the percentage of the HIV-specific CD4+ (panel A) or CD8+ (panel B) T-cells (red = MVA/FP; blue = MVA/MVA; groups include all participants in Part B of the study, plus those from Part A who received the same regimen and dosage as the Part B groups) that are producing one, two or three cytokines for positive responders detected by intracellular staining assay. The right graph depicts the γ-interferon (IFN-γ), interleukin-2 (IL-2) or tumor necrosis factor-α (TNF-α) in those cells producing one cytokine (1st panel on right), and the percentage of cells co-producing cytokine pairs in those producing two cytokines (2nd panel on the right). The boxplots indicate the median and IQR; whiskers extend to the furthest point within 1.5 times the IQR from the upper or lower quartile.

Figure 5

Figure 5. HIV-specific Interferon-γ ELISpot assay response rates and magnitude of background-adjusted spot forming cells (SFCs) per 106 PBMC induced by heterologous vector (M/F) and homologous vector (M/M) regimens

Total is the response to Env, Gag, Pol and/or Nef peptide pools. Responders are shown in colored circles (red = M/F; blue = M/M; groups include all participants in Part B of the study, plus those from Part A who received the same regimen and dosage as the Part B groups) and non-responders in gray triangles. The boxplots show the distribution of responses in positive responders only. The box indicates the median and interquartile range (IQR); whiskers extend to the furthest point within 1.5 times the IQR from the upper or lower quartile. Numbers at the top of each panel show the number of responders / number with assay result and the percent with positive response. Pol and Nef are not shown due to infrequent responses.

References

    1. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science. 2008;321:530–2. - PubMed
    1. Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008;320:760–4. - PubMed
    1. Letvin NL. Moving forward in HIV vaccine development. Science. 2009;326:1196–8. - PubMed
    1. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–5. - PMC - PubMed
    1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–10. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources